Using an independent discovery cohort of 292 patients, we identified a significant difference in expression in Ki-67 and p53 within ER+ cancers, which was associated with differences in clinical outcomes (breast-cancer specific death; CM McNeil et al, manuscript in preparation). The gene discussed is MKI67; the disease is breast carcinoma.